News (81)

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results GL
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results GL
Xilio Therapeutics : Corporate Update Call PU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program BU
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program AQ
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference GL
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference AQ
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference GL
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference AQ
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies GL
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies AQ
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results AQ
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer GL
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer AQ
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference GL
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results GL
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer GL
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results GL
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results AQ
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results GL
ReFrame and IMDbPro Announce 2022 ReFrame Stamp Film Recipients BU
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit GL
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day GL
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day AQ
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results AQ
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results GL
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President GL
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President GL
XILIO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer GL
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results GL
Xilio Therapeutics : Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results - Form 8-K PU
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results GL
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference AQ
Adagio Therapeutics : Announces David Hering Appointed Interim Chief Executive Officer - Form 8-K PU
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day AQ
Xilio Therapeutics : Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results - Form 8-K PU
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results AQ
X4 PHARMACEUTICALS, INC : Change in Directors or Principal Officers (form 8-K) AQ
X4 Pharmaceuticals, Inc. Approves Resignation of Ren? Russo as Director CI
123NextSee all

Companies (14)

BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 1 100 M $
Logo Beijing Tong Ren Tang Chinese Medicine Company Limited

Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Ch ...

CHINA RUNJI CEMENT INC. 78 $
Logo China Runji Cement Inc.

China Runji Cement Inc. is the owner of a cement production and distribution company in mainland China through its ownership of Anhui Province Runji Cement Co., Ltd. (Anhui Runji). Anhui Runji is a producer and distributor of cement, primarily in An Hui P ...

FEIYU TECHNOLOGY INTERNATIONAL COMPANY LTD. 63 M $
Logo Feiyu Technology International Company Ltd.

Feiyu Technology International Co., Ltd. is an investment holding company principally engaged in the development and operation of mobile games and Web games. The Company’s principal markets include both domestic market and overseas markets, including Ho ...

NAN REN LAKE LEISURE AMUSEMENT CO., LTD. 95 M $
Logo Nan Ren Lake Leisure Amusement Co., Ltd.

NAN REN Hu LEISURE AMUSEMENT CO., LTD. is a Taiwan-based company principally engaged in sports and entertainment business, as well as the provision of travel related services. The Company provides resort accommodation; leisure, conference and sports facil ...

CHINA SXT PHARMACEUTICALS, INC. 764 243 $
Logo China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TC ...

TONG REN TANG TECHNOLOGIES CO. LTD. 947 M $
Logo Tong Ren Tang Technologies Co. Ltd.

Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine pro ...

TEN REN TEA CO., LTD. 96 M $
Logo Ten Ren Tea Co., Ltd.

Ten Ren Tea Co., Ltd. is a Taiwan-based company principally engaged in the production and distribution of tea leaves, tea sets and beverages. The Company provides specialty tea products, such as oolong tea, packaged tea products, tea gifts, tea sets, tea ...

REN - REDES ENERGÉTICAS NACIONAIS, SGPS, S.A. 1 786 M $
Logo REN - Redes Energéticas Nacionais, SGPS, S.A.

REN - Redes Energéticas Nacionais, SGPS, S.A. specializes in the operation and concession management of the Portuguese electricity transportation network. Net sales break down by activity sector as follows: - electricity (63.7%): transportation of electr ...

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED 3 262 M $
Logo Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's bus ...

FIRST SPONSOR GROUP LIMITED 942 M $
Logo First Sponsor Group Limited

First Sponsor Group Limited is an investment holding company. The principal activities of the subsidiaries are those relating to investment holding, property development and sales, property investment, hotel ownership and operations and provision of prope ...


12Next

Insiders


Picture Leslie Russo
Leslie Russo

Leslie Russo is currently a member of the Health Care Compliance Association and the Society for Human Resource Management.
Previously, she worked as the Vice President of Human Resources and Compliance at NAPA Management Services Corp.
from 2006 to 2018.
She also held the position of Vice President of Human Resources and Compliance at North American Partners in Anesthesia LLP and Senior Vice President of Operations at Health Plus Management LLC.
Russo earned an undergraduate degree and an MBA from Jacksonville State University.


Picture Eric Russo
Eric Russo

Eric Russo has been working as the Vice President of Sales & Marketing at Cannon Group since 2012.
He holds a Master's degree in Business Administration from Villanova University.


Picture Augustus J. Russo
Augustus J. Russo

Augustus J.
Russo
is currently the Chief Creative Officer at AMI Entertainment Network LLC.
Previously, he worked as a Creative Director at Merit Industries, Inc. Russo received an undergraduate degree from The Pennsylvania State University.


Picture Carol P. Russo
Carol P. Russo

Carol P.
Russo
currently works as a Director at Miami Lighthouse For The Blind & Visually Impaired, Inc.


Picture Stuart Russo
Stuart Russo

Mr. Stuart Russo is Capital Advisor at HGGC LLC.
Mr. Russo received his Bachelor of Science Degree in Business Administration from the Roth School of Business, CW Post College of Long Island University in 1971.
He also attended the New York University Graduate School of Business Administration.




Picture Francesca Russo
Francesca Russo

Francesca Russo worked as an Associate Analyst at Moody's Italia Srl.


No results for this search